National Institute of Mental Health (NIMH)
Also known as: NIMH
Data updated
U.S. federal institute defining mental-health research agendas and evidence-generation priorities including psychedelic-relevant studies.
Academic Research
0 papersPublished Papers
0
Trial Involvement
27
Distinct Focus Topics
0
Latest Publication
Unknown
Entity type: Research Centre / Institute
Government Funding Snapshot
Grants, Subsidies & ContractsFunding Body
Health / Medical Research Funder
Jurisdiction
National
Coverage
1 country
Last Verified
Apr 11, 2026
Support Mechanisms
Verification
Verified
Psychedelic Engagement
Explicit Psychedelic Focus
Program Status
Active
Funding Programs
NIMH psilocybin project portfolio (RePORTER)
Jan 1, 2026
Internal query on 2026-04-11 identified active NIMH psilocybin awards.
NIH RePORTER API endpointPublic Sector Governance Snapshot
National Ministries & Federal AgenciesAuthority Type
National Ministry / Department
Jurisdiction
National
Coverage
1 country
Framework Status
Active
Function Areas
Governance Notes
Wave 2 governance enrichment for National Institute of Mental Health (NIMH).
Verification
Verified
Psychedelic Engagement
Explicit Psychedelic Focus
Last Verified
Apr 13, 2026
Research journey
Built from the 7 trials National Institute of Mental Health (NIMH) has sponsored, placed at the date each one started.
Featured in topic journeys
Clinical research timelines that include a curated milestone from National Institute of Mental Health (NIMH).
Quick Facts
- Type
- government
- Website
- Visit
Research Landscape
What the registered trials National Institute of Mental Health (NIMH) sponsors or participates in look like when you line them up. Counts come from Blossom’s trial records as of August 2026.
How fast is National Institute of Mental Health (NIMH) research growing?
SourcedRegistered trials by recorded study-start year; 1 earlier trial began before 2012. Click a year for the running total.
Don't read as total research effort: only registered trials with a recorded start date are counted (31 of 31 tracked). Recent years under-count because of registration lag; striped bars are still filling in or are planned starts.
What's live right now, and what stopped?
SourcedRegistry status of all 31 National Institute of Mental Health (NIMH) trials Blossom tracks. Orange marks trials recruiting or opening.
- Recruiting or opening
- 1445%
- Underway, not recruiting
- 13%
- Completed
- 1135%
- Stopped early
- 310%
- Unknown / other
- 26%
Don't read stopped trials as failures: trials end early for funding, recruitment, and strategy reasons too. Status is as last synced from the registry; some 'recruiting' trials may already have finished.
Which conditions does National Institute of Mental Health (NIMH) run trials on?
SourcedTrials per primary indication. Orange marks the largest research focus.
Don't read shares as adding to 100%: a trial with several primary indications counts once per indication. Trial volume signals research attention, not evidence quality.
Which compounds appear in National Institute of Mental Health (NIMH) trials?
SourcedTrials per compound. Orange marks the most-studied compound.
Don't read shares as adding to 100%: a trial testing several compounds counts once per compound, and placebo comparator arms are not shown. Trial volume signals research attention, not evidence quality.
Sponsored Trials
7Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression
- Start Date
- Compounds
- Placebo
[11C]-(R)-Rolipram to Measure cAMP Signaling Before and After Ketamine
- Start Date
Long-term Observation of Participants With Mood Disorders
- Start Date
Phase 1 Evaluation of (2R,6R)-Hydroxynorketamine
- Start Date
- Compounds
- Ketamine, Placebo
Mechanism of Action Underlying Ketamine’s Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression
- Start Date
- Compounds
- Ketamine, Placebo
Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder
- Start Date
- Compounds
- Ketamine, Placebo
Rapid Antidepressant Effects of Ketamine in Major Depression
- Start Date
- Compounds
- Ketamine, Placebo
Where this pipeline sits in the field
National Institute of Mental Health (NIMH) runs late-stage trials that Blossom ranks by how soon a catalyst is expected, alongside every other Phase 2 and Phase 3 study in the field.
Collaborated Trials
20Psilocybin as a Novel Therapy for Residual Anhedonia
- Start Date
- Compounds
- Psilocybin, Placebo
Biomarker-Guided Antidepressant Selection
- Start Date
- Compounds
- Ketamine
Psilocybin Therapy for Psychological Distress in Palliative Patients (PsyPal)
- Start Date
- Compounds
- Psilocybin
Ketamine Pharmacokinetics and Pharmacodynamics for Postpartum Depression and Pain After Cesarean Delivery (PREPARE-2)
- Start Date
- Compounds
- Ketamine
Cognitive Training as an Adjunct to Ketamine in Real-world Clinics
- Start Date
Examining Mu Opioid Mechanisms of Ketamine’s Rapid Effects in OCD (MKET2) (MKET2)
- Start Date
- Compounds
- Ketamine, Placebo
Neural Circuit Effects of Ketamine in Depression
- Start Date
- Compounds
- Ketamine, Placebo
Gamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression
- Start Date
- Compounds
- Ketamine, Placebo
Enhancing Week-long Psychological Treatment for PTSD With Ketamine
- Start Date
- Compounds
- Ketamine
Glutamatergic Adaptation to Stress as a Mechanism for Anhedonia and Treatment Response With Ketamine
- Start Date
- Compounds
- Ketamine, Placebo
Ketamine Versus Midazolam for Recurrence of Suicidality in Adolescents
- Start Date
- Compounds
- Ketamine
Ketamine Treatment of Youth Suicide Attempters
- Start Date
- Compounds
- Ketamine, Placebo
Reducing Adolescent Suicide Risk: Safety, Efficacy, and Connectome Phenotypes of Intravenous Ketamine
- Start Date
- Compounds
- Ketamine
Cognitive Behavioral Therapy Following Esketamine for Major Depression and Suicidal Ideation for Relapse Prevention (ENDURE)
- Start Date
- Compounds
- Esketamine
IM Ketamine vs Midazolam for Suicidal ER Patients
- Start Date
- Compounds
- Ketamine
Glutamatergic Mechanisms of Psychosis and Target Engagement (SA1)
- Start Date
- Compounds
- Ketamine
Efficacy of Psilocybin in OCD: a Double-Blind, Placebo-Controlled Study
- Start Date
- Compounds
- Psilocybin, Placebo
Physiological and Cognitive Biomarkers for Ketamine’s Antidepressant Effects
- Start Date
- Compounds
- Ketamine
miRNAs, Suicide, and Ketamine – Plasma Exosomal microRNAs as Novel Biomarkers for Suicidality and Treatment Outcome
- Start Date
- Compounds
- Ketamine
Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD)
- Start Date
- Compounds
- Ketamine, Placebo
Recent activity
- CompletedKetamine Versus Midazolam for Recurrence of Suicidality in Adolescents (NCT04592809, ketamine)
- StartedPsilocybin Therapy for Psychological Distress in Palliative Patients (PsyPal) (NCT06782724, psilocybin)
- CompletedCognitive Behavioral Therapy Following Esketamine for Major Depression and Suicidal Ideation for Relaps… (NCT04760652, esketamine)
- NewsJonathan Sabbagh of NIMH’s Division of Translational Research presented a concept to advance rigorous research into the mechanisms and therapeutic potential of fast-acting psychotomimetic agents.NIH
- NewsResearchers designed and synthesised (+)-JRT, an LSD analogue with lower hallucinogenic potential that promoted cortical neuroplasticity and therapeutic-like effects in preclinical models.NIH
- StartedKetamine Pharmacokinetics and Pharmacodynamics for Postpartum Depression and Pain After Cesarean Delivery… (NCT06767566, ketamine)
- TerminatedReducing Adolescent Suicide Risk: Safety, Efficacy, and Connectome Phenotypes of Intravenous Ketamine (NCT04613453, ketamine)
- StartedCognitive Training as an Adjunct to Ketamine in Real-world Clinics (NCT06526078)